MASSACHUSETTS GENERAL HOSPITAL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1811-01-01
- Employees
- -
- Market Cap
- -
FDA-Approved Alzheimer's Drug Lecanemab Shows Manageable Safety Profile in Real-World Setting
• WashU Medicine researchers found only 1% of Alzheimer's patients treated with lecanemab experienced severe side effects requiring hospitalization, confirming clinical trial safety data in a real-world setting.
• Patients with very mild Alzheimer's symptoms showed significantly lower risk (1.8%) of adverse events compared to those with mild symptoms (27%), suggesting earlier treatment may optimize both efficacy and safety.
• The study of 234 patients demonstrates that specialized memory clinics can effectively manage ARIA (amyloid-related imaging abnormalities), with most cases being asymptomatic and resolving without intervention.
Hillhurst Bio Secures $6.3 Million in Grants to Advance Novel Parkinson's Disease Treatment
• Hillhurst Biopharmaceuticals has received $6.3 million in grants, including $2 million from The Michael J. Fox Foundation and $4.3 million from the Farmer Family Foundation in collaboration with Massachusetts General Hospital.
• The funding will support a Phase 2a clinical trial evaluating Hillhurst's innovative liquid drug therapy designed to protect against Parkinson's disease progression through cytoprotective pathways.
• The 36-participant study, scheduled to begin in early 2025, will assess safety, pharmacokinetics, and biomarkers associated with a 14-day dosing regimen of the novel therapeutic approach.
First Patient Enrolled in Clinical Trial Evaluating RELiZORB for Pancreatitis Patients with EPI
• Massachusetts General Hospital has enrolled the first patient in a trial evaluating RELiZORB's efficacy in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients.
• RELiZORB is the only FDA-cleared enzyme device designed to mimic pancreatic lipase function, improving fat absorption for tube-fed patients with malabsorptive conditions.
• This investigator-initiated trial is one of four ongoing clinical studies evaluating RELiZORB's safety and efficacy across various malabsorptive conditions, including pancreatitis, short bowel syndrome, and critical care.
FDA Requests Additional Trial for Novavax COVID-19 Vaccine Before Full Approval
• The FDA has asked Novavax to conduct an additional randomized, controlled study of its COVID-19 vaccine NVX-CoV2601 before considering full approval, despite the vaccine having emergency use authorization since 2022.
• Interim results from a phase 2/3 study showed Novavax's updated XBB.1.5 variant vaccine generated 5.8 times higher neutralizing antibody levels compared to the original formulation, with a favorable safety profile.
• The FDA's request represents a significant setback for Novavax, which had expected approval based on prior conversations with regulators and had already passed its April 1 PDUFA date.
Varenicline Shows Promising Results for Youth Vaping Cessation in Landmark Trial
• A groundbreaking clinical trial reveals varenicline combined with remote behavioral counseling achieved 51% vaping abstinence rates in youth compared to 14% with placebo during the final four weeks of treatment.
• The study, published in JAMA, is the first pharmacotherapy trial for nicotine vaping cessation specifically targeting individuals aged 16-25, addressing a critical gap in treatment options for this vulnerable population.
• Despite some adverse events like nausea and vivid dreams, varenicline was generally well-tolerated, offering a potential evidence-based intervention for the 7.8% of high school students and 24.1% of young adults who reported recent e-cigarette use.
Blood Test Innovations: CBC Analysis Could Revolutionize Disease Detection and Monitoring
• New research shows that complete blood count (CBC) tests can identify or predict multiple diseases including heart problems, type 2 diabetes, osteoporosis, and kidney disease by analyzing individual "set points" in blood components.
• Massachusetts General Hospital researchers found that CBC variations between healthy individuals can provide personalized insights, with certain blood markers associated with 2-4 fold relative risk stratification for various diseases.
• Another breakthrough study demonstrates that phosphatidylethanol (PEth) blood testing accurately reflects alcohol consumption and liver damage, potentially offering more reliable assessment than patient self-reporting.
Excessive Sedentary Time Linked to Increased Cardiovascular Risk, Even in Active Individuals
• New research reveals that more than 10.6 hours of daily sedentary behavior significantly increases risk of heart failure and cardiovascular mortality, even among those meeting exercise guidelines.
• A complementary study from the University of Colorado demonstrates that prolonged sitting accelerates heart aging through negative impacts on cholesterol levels and BMI, with vigorous exercise only partially offsetting these effects.
• Researchers recommend replacing sitting time with physical activity, using standing desks, and incorporating at least 30 minutes of vigorous daily exercise to mitigate cardiovascular risks.
FDA Approves ANI Pharmaceuticals' Cortrophin Gel Prefilled Syringe for Multiple Autoimmune Conditions
• ANI Pharmaceuticals receives FDA approval for a new prefilled syringe format of Cortrophin Gel, available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options.
• The new presentation simplifies administration for patients using Cortrophin Gel therapy while maintaining its established efficacy in treating various autoimmune and inflammatory conditions.
• Commercial availability is expected in the second quarter of 2025, expanding ANI's Rare Disease portfolio and improving treatment accessibility for patients.
Celldex Advances Barzolvolimab Phase 3 Program in Chronic Urticaria with Strong Pipeline Progress
• Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.
• The company's Phase 2 CSU study demonstrated unprecedented efficacy with 71% of patients achieving complete response at Week 52, setting a new standard in disease treatment.
• Celldex expands its portfolio by initiating Phase 2 trials in atopic dermatitis and launching CDX-622, their first bispecific antibody targeting inflammatory diseases.
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
• Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.
• The combination therapy showed particularly strong efficacy in ABC DLBCL subtype patients, achieving an 83% disease control rate with 4 responses and 1 stable disease out of 6 patients.
• Safety profile reveals grade 3 or higher adverse effects in 55.6% of patients, while genetic analysis indicates efficacy independent of MYD88 or CD79B mutations.
Novel Tesla MRI Head Coil to Advance Lithium Brain Imaging in Multiple Phase II Psychiatric Trials
• Alzamend Neuro partners with Tesla Dynamic Coils BV to develop a groundbreaking MRI head coil for measuring brain lithium levels across five Phase II clinical trials at Massachusetts General Hospital.
• The specialized coil will enable high-resolution whole-brain lithium imaging to compare AL001's performance against standard lithium carbonate in treating Alzheimer's disease, bipolar disorder, depression, and PTSD.
• Initial mouse studies suggest AL001 achieves optimal brain absorption with lower blood concentrations than lithium carbonate, potentially eliminating the need for therapeutic drug monitoring.
Tegoprubart Successfully Used in Second Pig-to-Human Kidney Xenotransplant at MGH
• Massachusetts General Hospital successfully performed its second pig-to-human kidney transplant using Eledon's tegoprubart as a key immunosuppressant, with the patient now off dialysis after two years.
• Tegoprubart, an anti-CD40L antibody, demonstrates potential in preventing organ rejection by blocking multiple costimulatory receptors, marking a significant advancement in xenotransplantation.
• The procedure, performed on January 25, 2025, represents a crucial milestone in addressing the global organ shortage crisis, with MGH planning two additional xenotransplants this year.
Roche Launches SKYLINE: Four-Year Prevention Trial for Gantenerumab in Early-Stage Alzheimer's
• Roche initiates SKYLINE study, enrolling 1,250 participants aged 60-80 with early biological markers of Alzheimer's but no cognitive impairment, to evaluate gantenerumab's effectiveness in disease prevention.
• The study represents a significant investment in Alzheimer's research, featuring collaboration with prestigious institutions including Banner Alzheimer's Institute and Massachusetts General Hospital.
• Gantenerumab offers a potential advantage with its subcutaneous home administration option, distinguishing it from competitors requiring clinical infusions.
China NMPA Approves Astellas' Zolbetuximab for Advanced Gastric and GEJ Adenocarcinoma
• China's NMPA has approved zolbetuximab (VYLOY™) for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
• Zolbetuximab is the first monoclonal antibody approved in China that targets the CLDN18.2 biomarker expressed in gastric tumor cells.
• Approval was based on Phase 3 GLOW and SPOTLIGHT trials, showing statistically significant improvements in progression-free and overall survival.
• Approximately 35% of Chinese patients with advanced gastric and GEJ cancers have tumors expressing the CLDN18.2 biomarker.
Xenotransplantation Advances: Pig Kidney Transplants Show Promise in Addressing Organ Shortage
• Towana Looney became the longest-living recipient of a pig kidney transplant, exceeding 60 days post-surgery, marking a significant milestone in xenotransplantation.
• Tim Andrews received a genetically-edited pig kidney at Massachusetts General Hospital, becoming the second living person with such a transplant and is now dialysis-free.
• United Therapeutics received FDA approval for a clinical trial of its UKidney, a gene-edited porcine kidney, signaling a move towards formal xenotransplantation studies.
• Researchers are sharing data and refining techniques to improve the safety and efficacy of pig organ transplants, addressing the critical shortage of human donor organs.
Rilzabrutinib Shows Promise in Phase 3 Trial for Immune Thrombocytopenia
• Rilzabrutinib demonstrated a durable platelet response in 23% of ITP patients, compared to 0% with placebo, meeting the primary endpoint of the LUNA 3 trial.
• Patients receiving rilzabrutinib were approximately three times more likely to achieve a platelet response than those on placebo.
• The trial also met key secondary endpoints, including reduced bleeding, decreased need for rescue therapy, and improved physical fatigue and quality of life.
• Rilzabrutinib is currently under regulatory review in the US and the EU, with a target FDA action date of August 29, 2025.
Real-World Data Suggests Elacestrant Offers Similar or Improved Outcomes in Advanced Breast Cancer
• A real-world analysis shows elacestrant demonstrates similar or slightly higher time to treatment discontinuation compared to the EMERALD trial.
• The median real-world time to next treatment with elacestrant was 6.43 months, and time to treatment discontinuation was 4.6 months.
• Patients with PIK3CA pathway alterations experienced worse outcomes with elacestrant, underscoring the need for precision medicine.
• Most patients received elacestrant beyond the second line of treatment, with outcomes remaining consistent across different lines of therapy.
Semaglutide Shows Promise in Reducing Alcohol Consumption and Cravings
• A new study reveals that semaglutide, known as Ozempic and Wegovy, significantly reduces alcohol cravings and consumption in individuals with alcohol use disorder.
• Participants on semaglutide experienced fewer heavy drinking days and decreased alcohol intake during lab tests compared to those on a placebo, indicating potential therapeutic benefits.
• The research suggests semaglutide's effects on alcohol cravings may surpass existing treatments, offering a promising avenue for addressing the unmet needs in alcohol use disorder.
• Further studies are warranted to explore semaglutide's long-term efficacy, optimal dosages, and safety, particularly for individuals without obesity or diabetes.
NIH Awards $74.5 Million Grant for Alzheimer's Prevention Trial in Colombian ADAD Kindred
• A new study has received a $74.5 million NIH grant to test Alzheimer's prevention strategies in a Colombian kindred with a genetic mutation causing early-onset Alzheimer's disease.
• The trial will initially use donanemab to remove amyloid plaques in mutation carriers, followed by a comparison of donanemab, RG6289, or a combination to prevent plaque recurrence.
• The study will enroll 200 cognitively unimpaired and mildly impaired mutation carriers and 40 non-carriers, with enrollment expected to begin in the fall of 2025.
• This research builds upon previous work in the same population and aims to accelerate the evaluation of promising Alzheimer's prevention therapies.
COVID-19 Infection During Pregnancy Does Not Impair Child's Neurodevelopment, Study Finds
• A new study indicates that children exposed to COVID-19 in utero do not show significant neurodevelopmental delays at ages 12, 18, and 24 months.
• The research examined data from over 2,000 mother-child pairs, with approximately 11% of mothers infected with COVID-19 during pregnancy.
• Follow-up analyses, considering factors like trimester of infection and fever, also found no significant differences in developmental outcomes.
• An accompanying editorial advises caution, noting potential limitations of the screening tool and conflicting findings from other studies.
© Copyright 2025. All Rights Reserved by MedPath